Clinical Trials : Pulmonary Fibrosis

Completed

Study Name: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Condition: Progressive Pulmonary Fibrosis
Date: 2026-01-10
Interventions: Specified dose on specified days

Completed

Study Name: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
Condition: Idiopathic Pulmonary Fibrosis
Date: 2026-01-10
Interventions: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity).300 mg EGCG (2 capsules) taken orally daily for 12 weeks.Dru

Completed

Study Name: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Date: 2026-01-10
Interventions: Orally via a tablet.

Completed

Study Name: A Study to Investigate Leramistat in Patients With IPF
Condition: Idiopathic Pulmonary Fibrosis
Date: 2026-01-10
Interventions: Drug: Leramistat

Completed

Study Name: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Condition: Progressive Pulmonary Fibrosis
Date: 2026-01-10
Interventions: Placebo administered QID

Completed

Study Name: A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Condition: Idiopathic Pulmonary Fibrosis
Date: 2026-01-10
Interventions: Vixarelimab will be administered as per the schedule specified in the respective arms.

COMPLETED

Study Name: Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Date: 2026-01-10
Interventions: A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.

Completed

Study Name: Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).
Condition: Idiopathic Pulmonary Fibrosis
Date: 2026-01-10
Interventions: Nitric oxide gas for inhalation

COMPLETED

Study Name: SVF for Treating Pulmonary Fibrosis Post COVID-19
Condition: Pulmonary Fibrosis
Date: 2026-01-10
Interventions: Subjects received an intravenous injection of autologous adipose-derived SVF.

COMPLETED

Study Name: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF
Condition: Idiopathic Pulmonary Fibrosis
Date: 2026-01-10
Interventions: Intravenous administration of a starting dose of the monoclonal antibody

Search for Clinical Trial Results

Pulmonary Fibrosis - 51 Studies Found

Status	Study
Completed	Study Name: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis Condition: Progressive Pulmonary Fibrosis Date: 2026-01-10 Interventions: Specified dose on specified days
Completed	Study Name: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients Condition: Idiopathic Pulmonary Fibrosis Date: 2026-01-10 Interventions: Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity).300 mg EGCG (2 capsules) taken orally daily for 12 weeks.Dru
Completed	Study Name: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2026-01-10 Interventions: Orally via a tablet.
Completed	Study Name: A Study to Investigate Leramistat in Patients With IPF Condition: Idiopathic Pulmonary Fibrosis Date: 2026-01-10 Interventions: Drug: Leramistat
Completed	Study Name: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) Condition: Progressive Pulmonary Fibrosis Date: 2026-01-10 Interventions: Placebo administered QID
Completed	Study Name: A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease Condition: Idiopathic Pulmonary Fibrosis Date: 2026-01-10 Interventions: Vixarelimab will be administered as per the schedule specified in the respective arms.
COMPLETED	Study Name: Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2026-01-10 Interventions: A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.
Completed	Study Name: Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF). Condition: Idiopathic Pulmonary Fibrosis Date: 2026-01-10 Interventions: Nitric oxide gas for inhalation
COMPLETED	Study Name: SVF for Treating Pulmonary Fibrosis Post COVID-19 Condition: Pulmonary Fibrosis Date: 2026-01-10 Interventions: Subjects received an intravenous injection of autologous adipose-derived SVF.
COMPLETED	Study Name: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF Condition: Idiopathic Pulmonary Fibrosis Date: 2026-01-10 Interventions: Intravenous administration of a starting dose of the monoclonal antibody